NYSE:NGVT - Ingevity Stock Price, Forecast & News

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Ingevity Corp (NYSE:NGVT) issued its earnings results on Wednesday, October, 23rd. The company reported $1.46 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.42 by $0.04. The firm had revenue of $359.90 million for the quarter, compared to analysts' expectations of $365.44 million. Ingevity had a net margin of 14.31% and a return on equity of 53.69%. Ingevity's revenue was up 15.6% on a year-over-year basis. During the same quarter last year, the company posted $1.16 earnings per share. View Ingevity's Earnings History.

Ingevity is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Ingevity.

Ingevity issued an update on its FY 2019 earnings guidance on Wednesday, October, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.28-1.3 billion, compared to the consensus revenue estimate of $1.33 billion.

8 Wall Street analysts have issued 1-year target prices for Ingevity's stock. Their forecasts range from $96.00 to $130.00. On average, they anticipate Ingevity's stock price to reach $110.38 in the next twelve months. This suggests a possible upside of 23.0% from the stock's current price. View Analyst Price Targets for Ingevity.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ingevity.

News coverage about NGVT stock has been trending somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ingevity earned a news impact score of -1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Ingevity.

Ingevity saw a decline in short interest during the month of November. As of November 15th, there was short interest totalling 982,000 shares, a decline of 8.2% from the October 31st total of 1,070,000 shares. Based on an average daily volume of 310,700 shares, the short-interest ratio is currently 3.2 days. Currently, 2.4% of the company's shares are sold short. View Ingevity's Current Options Chain.

Some companies that are related to Ingevity include FMC (FMC), Johnson Matthey (JMPLY), Huntsman (HUN), Ashland Global (ASH), W. R. Grace & Co (GRA), KURARAY CO LTD/ADR (KURRY), Univar (UNVR), Balchem (BCPC), Olin (OLN), Chemours (CC), Innospec (IOSP), PQ Group (PQG), GCP Applied Technologies (GCP), Livent (LTHM) and Innophos (IPHS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include Costco Wholesale (COST), NVIDIA (NVDA), General Electric (GE), Quaker Chemical (KWR), Paypal (PYPL), Zebra Technologies (ZBRA), AbbVie (ABBV), Boeing (BA), Pfizer (PFE) and UnitedHealth Group (UNH).

Ingevity's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (3.17%), Massachusetts Financial Services Co. MA (2.43%), Chilton Investment Co. LLC (1.56%), Rice Hall James & Associates LLC (1.17%), Ardevora Asset Management LLP (0.75%) and Copper Rock Capital Partners LLC (0.59%). Company insiders that own Ingevity stock include John C Fortson, Katherine Pryor Burgeson and Phillip John Platt. View Institutional Ownership Trends for Ingevity.

NGVT stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Chilton Investment Co. LLC, Millennium Management LLC, Calamos Advisors LLC, Copper Rock Capital Partners LLC, Pictet Asset Management Ltd., Chartwell Investment Partners LLC and Kornitzer Capital Management Inc. KS. Company insiders that have sold Ingevity company stock in the last year include John C Fortson, Katherine Pryor Burgeson and Phillip John Platt. View Insider Buying and Selling for Ingevity.

NGVT stock was bought by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, Stifel Financial Corp, Massachusetts Financial Services Co. MA, Rice Hall James & Associates LLC, Tygh Capital Management Inc., Squarepoint Ops LLC, Russell Investments Group Ltd. and Eagle Asset Management Inc.. View Insider Buying and Selling for Ingevity.

Shares of NGVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NGVT stock can currently be purchased for approximately $89.70.

Ingevity has a market capitalization of $3.75 billion and generates $1.13 billion in revenue each year. The company earns $169.10 million in net income (profit) each year or $4.13 on an earnings per share basis. Ingevity employs 1,750 workers across the globe.View Additional Information About Ingevity.

The official website for Ingevity is http://www.ingevity.com/.

Ingevity's mailing address is 5255 Virginia Avenue, North Charleston SC, 29406. The company can be reached via phone at 843-740-2300 or via email at [email protected]